Literature DB >> 25456000

Fever as a risk factor for increased response to vitamin K antagonists: a review of the evidence and potential mechanisms.

Timothy H Self1, Carrie S Oliphant2, Anne B Reaves2, Amy M Richardson3, Christopher W Sands4.   

Abstract

Numerous factors affect the response to vitamin K antagonists (VKA) including age, dietary vitamin K, other drugs, pharmacogenetics, and disease states. In antithrombotic guidelines, fever is mentioned as a factor that may increase response to VKA. The purpose of this article is to review the available evidence regarding the effect of fever on response to VKA, and to discuss possible mechanisms of this effect. We performed a search of the English literature from 1943 to June 2014, using the key words fever AND warfarin, acenocoumarol, phenprocoumon, coumarin anticoagulants and VKA; fever AND vitamin K dependent clotting factors II, VII, IX, and X. One animal investigation and 6 studies in humans suggest fever increases response to VKA, but one study did not find a significant effect. The magnitude of this effect is variable. Possible mechanisms for the increased effect of VKA associated with fever are increased catabolism of vitamin K dependent clotting factors, decreased vitamin K intake, and inhibition of VKA metabolism. More rigorous studies are needed to confirm that fever increases response to warfarin and other VKA.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Coumarin anticoagulants; Fever; Mechanisms; Vitamin K antagonists; Warfarin

Mesh:

Substances:

Year:  2014        PMID: 25456000     DOI: 10.1016/j.thromres.2014.10.015

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

1.  Warfarin-induced life-threatening bleeding associated with a CYP3A4 loss-of-function mutation in an acute limb ischemia patient: Case report and review of the literature.

Authors:  Xiao-Wei Ma; Chang-Ning Hao; Zhi-Chun Gu; Meng Ye; Min Li; Lan Zhang
Journal:  Exp Ther Med       Date:  2017-06-14       Impact factor: 2.447

2.  Follow-up and management of valvular heart disease patients with prosthetic valve: a clinical practice guideline for Indian scenario.

Authors:  Devendra Saksena; Yugal K Mishra; S Muralidharan; Vivek Kanhere; Pankaj Srivastava; C P Srivastava
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2019-01-28

3.  Semi-empirical anticoagulation model (SAM): INR monitoring during Warfarin therapy.

Authors:  Marco Bontempi
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-10-15       Impact factor: 2.745

4.  Development of a clinical prediction model for an international normalised ratio ≥ 4·5 in hospitalised patients using vitamin K antagonists.

Authors:  Albert R Dreijer; Joseph S Biedermann; Jeroen Diepstraten; Anouk D Lindemans; Marieke J H A Kruip; Patricia M L A van den Bemt; Yvonne Vergouwe
Journal:  Br J Haematol       Date:  2018-03-14       Impact factor: 6.998

5.  The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists.

Authors:  Chantal Visser; Joseph S Biedermann; Melchior C Nierman; Felix J M van der Meer; Anouk J W Gulpen; Yvonne C F Moors; Suzanne C Cannegieter; Willem M Lijfering; Marieke J H A Kruip
Journal:  Thromb Haemost       Date:  2022-03-04       Impact factor: 5.249

Review 6.  Advanced delivery strategies facilitating oral absorption of heparins.

Authors:  Guihua Fang; Bo Tang
Journal:  Asian J Pharm Sci       Date:  2020-01-09       Impact factor: 6.598

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.